Table 5

Factors associated with an achieved response during the first 6 months of receiving a first-line biologic

VariablesOR (95% CI)P values
Age at initiation of the biologic, >50  years vs ≤50  years0.78 (0.21 to 2.92)0.72
Female sex1.94 (0.52 to 7.17)0.32
Associated disease (excl. myelodysplastic syndrome)0.93 (0.25 to 3.34)0.91
Myelodysplastic syndrome0.14 (0.01 to 1.51)0.10
Disease duration from diagnosis to receiving a biologic, ≥24  vs  <24  months (median)0.60 (0.16 to 2.21)0.44
Associated non-biologic disease-modifying antirheumatic drug2.14 (0.55 to 8.38)0.27
Charlson’s score >00.70 (0.19 to 2.56)0.58
Previous manifestations before biologic
 Fever0.80 (0.22 to 2.92)0.73
 Arthralgia/arthritis0.64 (0.11 to 3.69)0.61
 Sternal, sternocostal and sternoclavicular chondritides5.00 (1.22 to 20.45)0.02
 Ophthalmological0.44 (0.12 to 1.64)0.22
 Respiratory tract0.69 (0.18 to 2.63)0.56
 Vestibular and cochlear1.06 (0.28 to 4.06)0.93
Antibodies
 Rheumatoid factors1.58 (0.14 to 17.21)0.71
 Antinuclear antibodies1.68 (0.40 to 7.07)0.48
Disease manifestations at onset of a biologic
 Nasal/auricular3.64 (0.90 to 14.61)0.07
 Arthralgia/arthritis0.58 (0.14 to 2.34)0.44
 Sternal, sternocostal and sternoclavicular chondritis3.95 (0.90 to 17.40)0.07
 Ophthalmological0.43 (0.09 to 2.09)0.29
 Respiratory tract1.07 (0.29 to 3.92)0.92
 Vestibular and cochlear0.83 (0.17 to 4.14)0.82
  • It is a univariate analyses.